Sept 3 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its experimental candidates that target ...
RICHARDSON, Texas--(BUSINESS WIRE)--ARGO, a leading provider of high-value technology and analytical-sciences software for the financial services and healthcare industries, announces today from Jack ...
Novartis (NYSE:NVS) (OTCPK:NVSEF) has expanded its collaboration with Argo Biopharma, with multi-asset license and option agreements worth up to $5.2B with the Chinese biotech for several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback